The purpose of this study is to look at how well the new investigational drug works in participants with non-diabetic chronic kidney disease. An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA). Additionally, finerenone is approved for use in patients with chronic kidney disease with diabetes, but this study will evaluate whether the new drug is safe for the participants with chonic kidney disease without diabetes and will determine how it affects the body.
You will be required to take 1 tablet of finerenone or placebo once daily. You will be asked to provide blood and urine samples and to fill out a questionnaire at each in-person study visit. Vital sings (pulse, blood pressure) will be collected at each-visit. An electrocardiogram (a test to see how your heart works) will be performed several times throughout the study.
$85 will be provide for completion of each in-person visit
UNC Eastowne Medical Office Building
100 Eastowne Dr, Chapel Hill, NC 27514, USA
Amy Mottl
Medicine-Nephrology
Clinical or Medical
Interventional
Kidneys and Liver
21-3122
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
